Sequence-specific single-stranded DNA-binding protein 2 (SSBP2) is a candidate tumor suppressor for human acute myelogenous leukemia (AML). Inducible expression of SSBP2 causes growth arrest and partial differentiation in AML cells. Here, we report that the adenoviral oncoprotein E1B55K directly binds to endogenous SSBP2 protein and sequesters it into juxtanuclear bodies in adenovirally transformed human embryonic kidney (HEK) 293 cells. Similarly, transient expression of E1B55K in IMR90 fibroblasts and HeLa cells result in the formation of juxtanuclear bodies containing SSBP2. When nuclear export of E1B55K is prevented, SSBP2 remains associated with E1B55K in nuclear foci. A requirement for intact microtubules to retain the integrity of the juxtanuclear bodies suggests them to be E1B55K containing aggresomes. The adenoviral E1B55K protein has been shown to localize to the Mre11 complex and p53 to aggresome structures; together with the viral E4orf6 protein, E1B55K recruits a cellular E3 ubiquitin ligase that induces degradation of Mre11 and p53. However, our present studies reveal that E1B55K does not degrade SSBP2. These data demonstrate that E1B55K targets the candidate leukemia suppressor SSBP2 and suggest that subverting its function may contribute to cell transformation by viral oncoproteins.
Introduction
Single-stranded DNA-binding protein 2 (SSBP2) was originally isolated as a gene disrupted and deleted in human acute myelogenous leukemia (AML) (Castro et al., 2002) . Frequent loss of SSBP2 protein expression is observed in human AML cell lines, and inducible expression of SSBP2 in AML cells restores partial differentiation and growth arrest that is accompanied by downregulation of c-MYC (Liang et al., 2005) . Mammalian SSBP2 is one of three closely related and ubiquitously expressed genes (Castro et al., 2002) . The function of these proteins (SSBP2, SSBP3 and SSBP4) is unknown, but analysis of sequence motifs suggests that SSBP proteins may possess a versatile array of functions. At the amino terminus is a tryptophan-rich motif similar to transcriptional repressor LEUNIG of Arabidopsis (Castro et al., 2002) . Also within the amino terminus is a highly conserved domain that binds the LIM domain-binding co-factor Ldb1 (Chen et al., 2002; van Meyel et al., 2003) . Physical interaction with Ldb1 allows SSBP to modulate activity of LIM-homeodomain genes and LIM-only genes in a differentiation pathway that is conserved in Drosophila, Xenopus and mice (Chen et al., 2002; van Meyel et al., 2003; Nishioka et al., 2005) . Recent evidence suggests that SSBP2 may be part of a stem cell leukemia factor (SCL), Ldb1-containing multi-protein complex required for erythroid differentiation (Schuh et al., 2005; Goardon et al., 2006) . In addition to regulating activity of transcription factors, SSBP proteins may also have inherent transcriptional activity (Wu, 2006) . SSBP3 is the human ortholog of a chicken gene CSDP that binds single-stranded pyrimidine-rich mirror repeats with high specificity (Bayarsaihan and Lukens, 1996) , although the functional significance of this interaction is unknown. The central region of these proteins is rich in glycine and proline residues, with weak similarity in proline richness and periodicity to a subunit of the single-stranded DNAbinding complex RPA (Castro et al., 2002) .
Sequestration of tumor suppressor proteins by viral oncoproteins is a mechanism commonly employed by oncogenic viruses (Ahuja et al., 2005; O'Shea, 2005; Weitzman and Ornelles, 2005; Felsani et al., 2006) . The adenoviral oncoproteins E1A and E1B55K cooperate to transform primary cells in culture (Endter and Dobner, 2004) . E1A stimulates the cell cycle by binding RB family proteins, resulting in their dissociation from the E2F transcription factor (Felsani et al., 2006) . Simultaneously, E1B55K inactivates the p53 pathway by inhibiting p53-mediated transcription, thereby preventing growth arrest and apoptosis (Yew and Berk, 1992; Yew et al., 1994; Teodoro and Branton, 1997; Martin and Berk, 1998) . During adenovirus infection, E1B55K also associates with the viral E4orf6 protein and cellular proteins, forming an E3 ubiquitin ligase complex that induces proteasomal degradation of p53 (Querido et al., 1997 (Querido et al., , 2001a Steegenga et al., 1998 Steegenga et al., , 1999 Cathomen and Weitzman, 2000; Wienzek et al., 2000; Harada et al., 2002) . The E1B55K/E4orf6 complex also degrades cellular DNA repair proteins to prevent a DNA damage response (Stracker et al., 2002; Carson et al., 2003) and is required for RNA transport and late protein synthesis during infection (Dobner and Kzhyshkowska, 2001; Flint and Gonzalez, 2003) .
In Ad5-transformed human embryonic kidney (HEK) 293 cells, most of the E1B55K protein is localized in a large juxtanuclear cytoplasmic body (Zantema et al., 1985; Brown et al., 1994) . Recent evidence suggests that the body has hallmarks of cellular aggresomes or cytoplasmic inclusion bodies formed at the microtubule-organizing center (MTOC) in response to misfolded or aggregated protein accumulation (Liu et al., 2005) . Sequestration of cellular proteins into aggresomes by viral proteins may be one strategy that is employed by the virus to inactivate host defenses (Araujo et al., 2005; Liu et al., 2005) . Although this prominent cytoplasmic body has been observed in adeno-transformed cells for over two decades, very little is known about its constituents.
We report here that endogenous SSBP2 is recruited by E1B55K and localized to the juxtanuclear body in transformed 293 cells. E1B55K is sufficient to alter the localization of SSBP2 and the two proteins physically interact. These findings raise the possibility that an interaction between SSBP2 and the E1B55K oncoprotein could play an important role in adenoviral transformation or the inactivation of host defenses.
Results

SSBP2 localizes to juxtanuclear bodies in HEK293 cells
Previous studies with transient expression of the epitope-tagged Drosophila SSBP suggested nuclear localization of the SSBP protein that was dependent on the SSBP-interacting domain of Chip, the Drosophila ortholog of Ldb1 (van Meyel et al., 2003) . We examined the localization of SSBP2 protein in human cells by immunofluorescence using a specific antibody characterized previously (Liang et al., 2005) . Two distinct patterns of localization were seen. In most cell lines, including myeloid leukemic lines and epithelial cells, SSBP2 localized predominantly to nuclear speckles. Faint cytoplasmic speckles were also seen in most cell types. This is shown for the normal human fibroblast cell line IMR90, HeLa cells and A549 cells (Figure 1a) . In IMR90 cells, there was discernible nucleolar localization.
SSBP2 localization observed in HEK 293 cells was distinct from that in any of the other cells analysed (Figure 1b) . In these cells, the most prominent feature was a striking large juxtanuclear phase-dense body. In 293 cells, paucity of nuclear and cytoplasmic SSBP2 speckles also suggests that the juxtanuclear body may be formed at the expense of the nuclear and cytoplasmic pools. We also examined the localization of the related family protein SSBP3 in 293 cells (Figure 1c) . The SSBP3 protein shares 83% identity to SSBP2 and is also found in Ldb1 containing transcriptional complexes (Goardon et al., 2006; Liang and Nagarajan, unpublished data) . Although very similar to SSBP2, this protein appeared to be predominantly nuclear and did not reside in cytoplasmic structures in 293 cells. To address whether the SSBP2-interacting protein Ldb1 also colocalized in the juxtanuclear body, Ldb1 localization was examined. Ldb1 localized primarily to the nucleus and therefore appears to be physically separated from SSBP2 in 293 cells (Figure 1d ). These results show that accumulation at the cytoplasmic body is specific to SSBP2.
The intensity of SSBP2 signal in 293 cells suggests that the protein levels may be higher in these cells (Figure 1b) . Consistent with this, an immunoblot of three cell lines, 293, MCF7 and IMR90, reveals the protein levels to be highest in 293 and lowest in IMR90 (Figure 1e ). At present, it is unclear whether the higher levels in 293 are due to the adenoviral proteins E1A and E1B expressed in these cells or the tissue of origin of these cells, as SSBP2 transcripts are varied in different tissues (Castro et al., 2002) .
SSBP2 is sequestered into aggresomes by adenoviral E1B55K
The dense cytoplasmic body adjacent to the nucleus where SSBP2 is located in 293 cells is similar to that observed for E1B55K in cells transformed by adenovirus (Zantema et al., 1985; Brown et al., 1994; Endter et al., 2005; Liu et al., 2005) . We therefore examined the relative localization of SSBP2 and E1B55K in 293 cells ( Figure 2 ). The predominant staining pattern for SSBP2 was in the aggresome structures with E1B55K, although some distinct staining was also observed for each protein.
Other proteins reported at these E1B55K structures include p53 and components of the MRN complex (Brown et al., 1994; Endter et al., 2005; Liu et al., 2005) . SSBP2 colocalized with p53 and Mre11 in the juxtanuclear body in 293 cells (Figure 2 ), whereas in all other cells the two proteins were diffusely nuclear (data not shown). Furthermore, the cytoplasmic body was in close proximity to the Golgi and surrounded by golgin-97 staining ( Figure 3a ).
These findings demonstrate that SSBP2 is a component of the E1B55K juxtanuclear body in 293 cells that has been defined as an aggresome. The formation of aggresomes is inhibited by the microtubule-depolymerizing agent nocodazole due to the dependence upon microtubules (Kopito, 2000) . It has been shown that treatment of 293 cells with nocodazole results in dispersal of the E1B55K aggresome into multiple smaller aggregates (Liu et al., 2005) . The aggresome was disrupted in nocodazole-treated cells, coincident with microtubule dispersion, which was detected by disorganized Golgi structure and the breakdown of the cytoplasmic microtubule network (Figure 3b ). Quantitation of the number of cells possessing a singlejuxtanuclear cytoplasmic aggregate indicated that B71% of untreated cells localize SSBP2 to the aggresome, and this was decreased to only B30% in nocodazole-treated cells (Figure 3c ). These findings are consistent with SSBP2 being sequestered into an aggresome that is structurally dependent upon microtubule assembly.
Localization of SSBP2 aggresomes is dependent upon E1B55K
If E1B55K is responsible for the relocalization of SSBP2, then expressing E1B55K transiently in other cell lines would be expected to induce the formation of the body. When an E1B55K expression vector was transfected into IMR90 fibroblasts, HeLa and A549 cells, localization of the endogenous SSBP2 protein was notably altered and the two proteins colocalized in large juxtanuclear bodies (Figure 4a ; data not shown). These results suggest that E1B55K mediates the sequestration of SSBP2 into the aggresome.
The E1B55K protein undergoes nucleocytoplasmic shuttling mediated by the CRM1-export pathway through the leucine-rich nuclear export signal (NES) at the N terminus (Kratzer et al., 2000; Dosch et al., 2001; Endter et al., 2005) . We examined the effect of blocking the CRM1-export pathway in 293 cells with Leptomycin B (LMB). Treatment of 293 cells with LMB resulted in colocalization of E1B55K together with SSBP2 and p53 in nuclear foci (Figure 4b ). This result suggests that the subcellular localization of SSBP2 in 293 cells involves CRM1-dependent trafficking of the E1B55K protein.
Additionally, when HeLa cells were transfected with a vector expressing an E1B55K mutant lacking the nuclear export signal (NES), the protein accumulated in intranuclear foci as reported previously (Endter et al., 2005) . We also observed that the endogenous SSBP2 (e) About 10 mg of whole-cell lysate from the cell lines were resolved on NuPage gel to visualize proteins in an immunoblot with SSBP2 antibodies as described previously (Liang et al., 2005) .
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HB Fleisig et al protein was reorganized into the nuclear foci with the NES mutant (Figure 4c ). Finally, coexpression of the adenoviral E4orf6 protein results in nuclear accumulation of E1B55K (Ornelles and Shenk, 1991; Cathomen and Weitzman, 2000) . When E4orf6 is expressed in 293 cells, SSBP2 is found to be colocalized with E1B55K in the nucleus and the aggresome is no longer apparent (Figure 4d) . Together these experiments demonstrate that E1B55K can impact the intracellular localization of SSBP2.
SSBP2 interacts directly with Ad2-E1B55K
To provide the biochemical basis for the colocalization, endogenous SSBP2 was immunoprecipitated from 293 cells. Subsequent immunoblotting revealed that E1B55K coprecipitates with SSBP2 (Figure 5a ), suggesting that E1B55K recruits SSBP2 either directly or through an unknown partner. To determine whether SSBP2 and E1B55K interact directly, we performed yeast two-hybrid interaction assays. Yeast cells transformed with plasmids expressing SSBP2 fused with a GAL4 activation domain (van Meyel et al., 2003) and Ad2 E1B55K fused to the GAL4 DNA-binding domain (Zhao et al., 2003) were selected on media lacking leucine and uracil, and an interaction was assessed by growth in media lacking adenine (Figure 5b ). We detected an interaction between the 1-200 amino terminal residues of SSBP2 and an Ad2 E1B55K construct containing residues 1-437. A protein with the amino terminal 100 residues of SSBP2 interacted with Ldb1 but not with E1B55K, suggesting that the E1B55K interacting domain resides within residues 100-200 of SSBP2. Collectively, the yeast two-hybrid assay and the coimmunoprecipitation data demonstrate a direct interaction between the amino-terminal of SSBP2 and E1B55K.
SSBP2 stability is not altered by E1B55K/E4orf6
The E1B55K protein forms part of an E3 ubiquitin ligase complex together with the adenoviral E4orf6 protein (Querido et al., 2001a; Harada et al., 2002) . The MRN complex and p53 are examples of proteins that interact with E1B55K, colocalize to aggresomes in 293 cells, and are degraded by E1B55K/E4orf6. We therefore examined whether SSBP2 is a target for degradation by E1B55K/E4orf6. Protein levels were assessed by 
E1B55K sequesters SSBP2
HB Fleisig et al immunoblotting in a HeLa cell line that stably expresses E1B55K (Carson et al., 2003) in the presence and absence of E4orf6 that was supplied by transduction with a recombinant adenovirus vector ( Figure 6 ). As demonstrated previously, the levels of endogenous Rad50 and Mre11 were decreased in cells expressing E1B55K and E4orf6 (Carson et al., 2003) . However, SSBP2 levels remained unaltered, suggesting that the interaction with E1B55K does not lead to SSBP2 becoming a target for degradation.
Discussion
Our results demonstrate for the first time that the E1B55K protein binds to SSBP2 directly and localizes it to the juxtanuclear body in adenovirally transformed 293 cells (Figures 1b and 2) . In normal IMR90 fibroblasts, SSBP2 localizes to nuclear and cytoplasmic speckles ( Figure 1a) . However, upon transient expression of E1B55K, endogenous SSBP2 reveals a localization pattern similar to that observed in HEK293 cells (Figure 4a ). It has been suggested that adenovirus exploits the cellular aggresome response to facilitate inactivation of cellular proteins (Araujo et al., 2005; Liu et al., 2005) . The juxtanuclear cytoplasmic bodies observed for E1B55K in adenovirus-infected cells, E1A/E1B-transformed cells and E1B55K-transfected cells have been demonstrated to be aggresomes (Liu et al., 2005) . They are located at the MTOC, surrounded by a vimentin cage, and are dependent upon the microtubule cytoskeleton analogous to what was observed for SSBP2 ( Figure 3 ). Proteins previously reported to localize with E1B55K in these aggresomes include vimentin, HSP70, p53, g-tubulin, Cul5, and the Mre11 complex (Zantema et al., 1985; Brown et al., 1994; Araujo et al., 2005; Liu et al., 2005) . A number of other cellular proteins interact with E1B55K (Harada et al., 2002) but their localization has not been determined in 293 cells.
Accumulation of SSBP2 at the aggresome is dependent upon E1B55K
This was demonstrated by the absence of juxtanuclear staining for SSBP2 when E1B55K was translocated into the nucleus by E4orf6 expression (Figure 4d ). Inhibition of E1B55K nuclear export by LMB treatment of 293 cells also demonstrated that E1B55K accumulated in nuclear foci together with aggresome components SSBP2 and p53 (Figure 4b ). This suggests that SSBP2 is probably exported from the nucleus in a complex with E1B55K. Evidence for a nuclear interaction also comes from the SSBP2 recruitment into nuclear foci by the E1B55K NES mutant (Figure 4c ). Some cellular proteins found interacting with E1B55K in the aggresome are degraded by the elongin BC/Cullin5/Rbx1 ubiquitin ligase that is recruited in the presence of E4orf6 (Querido et al., 2001a; Harada et al., 2002) . This does not however appear to be the case for SSBP2 (see Figure 6 ). Although E1B55K directly binds SSBP2, several other E1B55K interacting proteins (p53, Mre11, Rad50 and Nbs1) do not readily co-precipitate with SSBP2 under our immunoprecipitation conditions 
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(unpublished data). Therefore, SSBP2 may physically interact with E1B55K in a manner that is distinct from other complexes.
The reason for recruitment of SSBP2 into the E1B55K aggresome is not clear from the present findings. We do not believe that SSBP2 is essential for aggresome formation or maintenance since we did not detect dissolution of the aggresome when SSBP2 levels were decreased by RNA interference in 293 cells (Fleisig and Nagarajan, unpublished data). Sequestration of SSBP2 into the cytoplasmic body may neutralize SSBP2 function. The lack of aggresome accumulation for the known binding partner Ldb1 in 293 cells (Figure 1d) suggests that when SSBP2 is localized to this structure it may not readily interact with other factors required for its modulation of differentiation (Chen et al., 2002; van Meyel et al., 2003) . Identification of transcriptional targets for SSBP2 will shed further light on whether the differentiation response is inactivated by E1B55K binding. Alternately, E1B55K may recruit SSBP2 in order to harness a function during viral replication. The nucleolar localization observed in IMR90 cells, together with its observed weak sequence homology to RNA splice factor U1C, raises a potential role for SSBP2 in RNA metabolism (Castro and Nagarajan unpublished results) . The E1B55K protein is required to inhibit cellular RNA transport and promote viral RNA export during adenoviral infection, and this could involve harnessing of an SSBP2 function. We have observed that SSBP2 is also recruited into an aggresome in an E1B55K-dependent manner during adenovirus infection (unpublished data), but the relevance to productive replication is still unknown.
Originally isolated due to its disruption and loss of expression in human leukemia, SSBP2 now joins tumor suppressors p53 and WT1 as a potential target of E1B55K-mediated functional inactivation. Viral oncoproteins target multifunctional cell cycle regulators to inactivate nodal points in cellular circuitry. Further characterization of E1B55K and SSBP2 interaction may shed light on novel cellular pathways regulated by SSBP2 and will determine whether its functions are inactivated or exploited during transformation and virus infection.
Materials and methods
Cell culture
Human cell lines used in these studies were HEK 293 cells (Microbix Biosystems Inc., Ontario, Canada and Qbiogene Inc., Irvine, CA, USA), IMR90 fibroblasts, HeLa, A549 and MCF7 cells (ATCC, Manassas, VA, USA). All cells were maintained as monolayers according to the distributors' guidelines.
Plasmids and transfections
Vectors for wild-type and the NES mutant E1B55K expressing the protein were under the control of the CMV promoter. When cells were not going to be costained for E1B55K, transfected cells were detected by inclusion of a GFP reporter plasmid at a 1:10 ratio. IMR90 cells were electroporated with the pcDNA3.1/E1B55K plasmid (a kind gift from T Dobner) in an Amaxa Nucleofector II system using the Nucleofector kit R according to the manufacturer's protocol (Amaxa Inc., Gaithersburg, MD, USA). HeLa and 293 cells were transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to manufacturer's protocol. Cells were fixed 24 h after the start of transfection.
Antibodies
The following antibodies were used in this study: rat antiadenovirus 5 E1B55K (Calbiochem, San Diego, CA, USA), mouse monoclonal 2A6 (Sarnow et al., 1982) against E1B55K (gift from A Levine), rabbit anti-E4orf6 (gift from P Branton), rabbit anti-ldb1 (gift from A Agulnick) and mouse anti-golgin-97 is not degraded by E1B55K/E4orf6. Protein levels were assessed by immunoblotting of lysates from stable cells expressing either GFP or E1B55K in the absence or presence of E4orf6, supplied by transduction with an E1-deleted recombinant adenovirus for 24 h. Mre11 and Rad50 levels were decreased, but SSBP2 was unaffected. Ku86 served as a loading control.
(Molecular Probes, Invitrogen), p53 (1C12, Cell Signaling, Danvers, MA, USA), mouse monoclonals against Mre11, Rad50 (Gentex, San Antonio, TX, USA) and Ku86 (Santa Cruz, Santa Cruz, CA, USA). The rabbit polyclonal antibody specific for SSBP2 was generated and characterized previously (Liang et al., 2005) . A rabbit polyclonal antibody raised against a unique internal peptide was used to detect SSBP3. Secondary antibodies for immunofluorescence were conjugated to Texas Red or FITC fluorophores or Alexa Fluor 488 and 561 (Molecular Probes, Invitrogen). For immunoblotting by enhanced chemiluminescence, secondary antibodies were coupled to horseradish peroxidase (Jackson ImmunoResearch, West Grove, PA, USA).
Immunoprecipitation and immunoblotting
Whole-cell extracts were prepared in lysis buffer (500 ml/35 mm well) containing 0.2% NP-40, 40 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM ethylenediaminetetraacetic acid, 2 mM dithiothreitol, 10% glycerol, 50 mM NaF, 1 mM Na 3 OV 4 and protease inhibitors. Immunoprecipitation was performed overnight at 41C using anti-SSBP2 antisera. Immunoprecipates bound to Protein A-Sepharose beads (Amersham Pharmacia Biotech, Piscataway, NJ, USA) were washed and eluted in Â 2 sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample buffer. The samples were electrophoretically separated on NuPAGE gels (Invitrogen) either 4-12 or 10%, and transferred to polyvinylidene difluoride membrane (Amersham Biosciences, Piscataway, NJ, USA).
Immunoblots were developed using rabbit polyclonal antibodies to SSBP2 and E4orf6, and mouse monoclonals to E1B55K, Rad50, Mre11 and Ku86. The bound antibody was detected with enhanced chemiluminescence reagent ECL (Amersham Biosciences).
Immunofluorescence Cells plated on glass coverslips were transfected, fixed and analysed at 24 h after transfection. For LMB treatment, cells were incubated for 3 h in medium containing 10 nM LMB before fixation. For nocodazole treatment, cells were incubated with 10 mM nocodazole for 4 h. Cells were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 20 min, followed by permeabilization using 0.2% triton X-100 in PBS. The cells were washed and incubated in blocking buffer (PBS, 5% NGS, 2% BSA and 0.1% tween20) for 1 h at room temperature. Primary antibodies were added to blocking solution for 1 h at room temperature followed by secondary antibodies for 1 h at room temperature. Cells were washed four times in PBS and nuclear DNA was stained with 4 0 ,6-diamidino-2-phenylindole (DAPI). Coverslips were mounted using Fluoromount-G (Southern Biotechnology Associates, Birmingham, AL, USA) or Prolong antifade mounting medium (Molecular Probes, Invitrogen). At the MD Anderson Cancer Center Molecular Genetics Microscope Facility immunoreactivity was observed and images acquired with a Nikon 2000U inverted microscope in conjunction with Metamorph software. Autoquant's AutoDeBlur was used to process and analyse the images. At the Salk Institute Pendleton Microscopy Facility immunoreactivity was visualized using a Leica SP2 confocal microscope and associated software, or a Nikon microscope in conjunction with a CCD camera (Cooke Sensicam, Romulus, MI, USA) and processing using SlideBook and Adobe Photoshop.
Yeast 2-hybrid qualitative interaction assay SSBP2-pGAD plasmids were a gift from A Agulnick (CyThera Inc., La Jolla, CA, USA) and were previously published (van Meyel et al., 2003) . The E1b55K-pDG(U) plasmids and the mSin3A-positive control plasmids were a gift from D Liao (University of Florida), constructed and were published previously (Zhao et al., 2003) . Plasmids were transformed into yeast strain AVL257, ID PJ69-4A. Strain genotype MAT a Trp 1-90leu2-3, 112ura3-52his3-200gal4-Dgal80-GAL2-ADE2LYS2HGAL-HIS3met2HGAL7-lacZ. The transformation was tested for growth on plates lacking leucine and uracil. A positive result was scored by growth on plates lacking Adenine after 72 h at 301C.
